Labiotech.eu

In Depth 24 May 2017

What Happens when the Immune System Attacks Life-Saving Drugs?

Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how can we fight it? Immunogenicity can be a huge problem. Affecting especially protein-based drugs, this process consists in the development of anti-drug antibodies (ADAs) against a molecule that, in most cases, is saving the life […]

May 24, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Oryx glioblastoma ParvOryx combination 1

News and Trends 23 May 2017

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […]

May 23, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 May 2017

Norwegian Biotech Goes for Combination Therapies in Melanoma

BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […]

May 22, 2017 - 2 minutesmins - By Melanie De Almeida

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 May 2017

A Concert Played by Human Neurons on a Petri Dish

Guy Ben-Ary grew his own neurons on a Petri dish and made them perform in a concert last weekend at the Haus der Kulturen der Welt in Berlin. Last weekend I took my bike across Berlin to attend a truly unique event. It was, in fact, my first time going to a concert where one […]

May 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Hansa Medical EMA Priority liver transplant

More News! 19 May 2017

The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection

Hansa Medical has accessed the EMA’s priority medicines scheme to accelerate the development of a therapy that broadens the access to kidney transplants. Hansa Medical, based in Lund, Sweden, develops enzymes with immunomodulatory properties. Its lead candidate, IdeS, has now been granted access to the EMA’s priority medicines (PRIME) scheme, designed to support the development […]

May 19, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Iterum Therapeutics antibiotics series b fundraising

News and Trends 19 May 2017

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Iterum Therapeutics has raised €58M to fund Phase III and bring a new antibiotic to a market where innovation is lacking. Iterum Therapeutics is a biotech based in Dublin that develops new antibiotics with the aim of combating the superbug crisis. The company has just raised €58M ($65M) in Series B to fund Phase III […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 May 2017

Shining new Light on how to control Cell Circuits

Controlling genes with light is a new therapeutic avenue, and researchers from Finland are exploring how it can be used to tinker with the cell’s biochemical circuitry. Their findings could provide a better understanding of degenerative diseases and yield new cancer treatments. Researchers from the Turku Centre for Biotechnology at the University of Turku and Åbo […]

May 19, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 18 May 2017

#Live# Labiotech Hangout: Join our first webcast on anti-aging therapies!

As we grow as a company, our content is growing too! Hang out with us and anti-aging VC managing partner, James Peyer, online next week. Join Now! We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week, we’re trying out a new feature and bringing additional […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What Happens when the Immune System Attacks Life-Saving Drugs?

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Norwegian Biotech Goes for Combination Therapies in Melanoma

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

A Concert Played by Human Neurons on a Petri Dish

The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Shining new Light on how to control Cell Circuits

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

#Live# Labiotech Hangout: Join our first webcast on anti-aging therapies!

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!